Drug discovery biology

Drug discovery biology

The Drug Discovery Biology research teams within the Monash Institute of Pharmaceutical Sciences have broad expertise in receptor molecular and cellular biology, whole-animal studies and translational discovery research.

DDB laboratories

Research in the Drug Discovery Biology Theme is conducted by independently-funded groups that share core facilities and infrastructure. We are supported by government grant schemes and key industry partnerships, and collaborate extensively with national and international researchers.

Therapeutic foci

Front lawn of Monash Parkville campus

Our doctoral program

The Drug Discovery Biology doctoral PhD offers an elite program in a world class scientific environment to ensure our graduates are not only specialists in their chosen scientific field, but also have an understanding of diverse topics, techniques and practices relevant to drug discovery.

Find out more

Drug discovery biology PhD student

Research Capabilities

Our research is underpinned by a broad range of experimental approaches.

Researchers

A-Z list of all research staff

DDB news

Watch

Explore our videos to learn more about our research and postgraduate opportunities.

Latest news from MIPS


Contact us

Email: pharm-ddb-enquiries@monash.edu

Telephone: +61 3 9903 9614

.

For prospective postgraduate students

See the latest news

Scientists develop novel tools to gain new insights into an important therapeutic target

A team of researchers, led by the Monash Institute of Pharmaceutical Sciences (MIPS) have, for the first time, developed a tool that will enable the wider scientific community to gain a deeper understanding of how the human adenosine A1 receptor
Research
Model diseased heart

Australian researchers drive global call to action to tackle world’s leading cause of death

A team of Australian drug researchers from Monash University, The University of Sydney and La Trobe University have led a global call to action to accelerate new approaches for cardiovascular disease (CVD) drug solutions. CVD is the leading cause of

Monash University researchers discover potential therapeutic target to reduce diabetes-induced heart failure

Researchers from the Monash Institute of Pharmaceutical Sciences (MIPS), in collaboration with The Baker Heart and Diabetes Institute, have discovered a potential therapeutic target which could reduce heart failure and may improve the quality of

Researchers identify off switch for alcoholism

Researchers from Monash University and the Florey Institute have made a potential breakthrough in the ability to treat alcohol addiction with a simple drug.

Professor Mark Febbraio wins the 2020 GSK Award for Research Excellence

Professor Mark Febbraio from the Monash Institute of Pharmaceutical Sciences (MIPS) has become the 40th winner of the prestigious GSK Award for Research Excellence.

Monash University scientist wins prestigious Eureka Prize for ground-breaking research into treating metabolic disease

Professor Mark Febbraio from the Monash Institute of Pharmaceutical Sciences (MIPS) has been awarded the 2020 Australian Museum Eureka Prize, the nation’s top science award.

Leading Australian metabolic disease researcher wins Society of Endocrinology International Medal

Prominent metabolic disease researcher Professor Mark Febbraio, from the Monash Institute of Pharmaceutical Sciences (MIPS), has been awarded the 2021 International Medal from the UK’s Society of Endocrinology.

Breakthrough discovery paves the way for preventing sugar-induced liver disease

A team of international researchers including Monash University academics has discovered that, contrary to previous belief, fructose causes liver toxicity by changing the barrier function of the intestine.

New international collaboration showcases drug development potential

New research from Monash Institute of Pharmaceutical Sciences (MIPS), in collaboration with the Max Planck Institute, Mayo Clinic, University of Auckland, University of Essex and University of Tokyo, has uncovered new structures of protein